SEMA4
pschott@stamfordadvocate.com; twitter: @paulschott
FROM THE FRONT PAGE
company’s exit from the “somatic” tumor-testing business — an area of operations that represents less than 1 percent of the company’s revenues, but about $35 million in annual expenses.
At the same time, Sema4 said it was moving its hereditary...
Read latest New Haven Register (New Haven, CT) online.
Online newspapers
at PressDisplay.